This study tests a new treatment for head and neck cancer, using a monoclonal antibody called VX15/2503. A monoclonal antibody is a special medicine that can stop cancer cells from growing and spreading. The study looks at how well VX15/2503 works alone or with other medicines called ipilimumab and nivolumab, which help the immune system fight cancer. Patients will be randomly placed in one of six groups, with some receiving VX15/2503 alone or with the other medicines, and others having surgery only. The study checks how these treatments affect the body’s immune system and ensures they are safe.
- Participants will need to have surgery between days 17-36 of the study.
- Some groups will get an additional medicine through an IV drip on the first day.
- Participants must be willing to follow study rules and attend all appointments.
How understandable was the trial content above?
Hard to understand
Easy to understand